Navigation Links
Clinical Trial Testing New Multiple Sclerosis Treatment to Launch in Buffalo
Date:6/28/2010

Researchers at the University at Buffalo, led by the Department of Neurosurgery, will embark on a landmark prospective randomized double-blinded study to test the safety and efficacy of interventional endovascular therapy—dubbed “liberation treatment”—on MS symptoms and progression.

(Vocus) June 28, 2010 -- Recently, chronic cerebrospinal venous insufficiency (CCSVI) has been strongly associated with multiple sclerosis (MS). In a series of original studies, Dr. Paolo Zamboni of the University of Ferrara, Italy demonstrated blockage of major venous outflow from the brain and spinal cord in patients with MS. Researchers from many institutions, including the University at Buffalo, have confirmed the association.

It is hypothesized that the narrowing in the large veins in the neck and chest might cause improper drainage of blood from the brain, resulting in eventual injury to brain tissue. It is thought that angioplasty—a treatment commonly used by cardiologists and other endovascular surgeons to treat atherosclerosis—may remedy the blockages. Dr. Zamboni has further conducted preliminary studies suggesting the efficacy of venous angioplasty (“liberation procedure”) in the amelioration of MS symptoms.

Now, researchers at the University of Buffalo will launch PREMiSe (Prospective Randomized Endovascular therapy in Multiple Sclerosis) to determine if endovascular intervention via balloon angioplasty to correct the blockages improves MS symptoms or progression. PREMiSe is believed to be the first IRB-approved prospective randomized double-blinded study of balloon angioplasty for MS being performed in a rigorous fashion in the US with significant safeguards in place to ensure careful determination of risks and benefits.

The study is being led by principal investigator Dr. Adnan Siddiqui along with co-principal investigators Dr. Ela
'/>"/>

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related medicine news :

1. US Department of Defense helps move spinal cord injury treatment closer to clinical trials
2. Almac's US Headquarters Will Address Capacity Demand for Clinical Supplies
3. Second Ohio State cancer drug begins clinical trials testing
4. Genealogy may affect clinical differences in systemic lupus erythmatosus patients
5. BRAF inhibitor shows promising preclinical activity against melanoma
6. Sunrise Services Wins the Gold in Medisoft Clinical Sales Contest
7. European patient survey add weight to expert call for greater clinical consensus on BTCP
8. FDA approves first human neural stem cell clinical trial to treat brain tumors
9. Antibody therapy lengthens survival of metastatic melanoma patients in large clinical trial
10. Vandetanib shows clinical benefit when combined with docetaxel for lung cancer
11. Fox Chase clinical trial tests first of its kind antibody
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Ontario (PRWEB) July 31, 2014 Setting goals ... seen on blogs on successful tips to weight loss. Fitness ... goals for over 8 years, and has worked with 6000 ... trainers. “We have had the chance to monitor why customers ... stop exercising, how long they stick to their program, whether ...
(Date:7/31/2014)... July 31, 2014 The VitalSleep anti snoring device ... forward to help open a snorers airway to quiet snoring. ... helped her relationship with her husband by allowing them to ... years old. My snoring began about 15 years ago and I ... children could not sleep and had to head downstairs for any ...
(Date:7/31/2014)... 31, 2014 The controversy surrounding ... LLP notes that Johnson & Johnson’s Ethicon, Inc. ... remove its power morcellators ( http://www.gynecaremorcellatorlawsuit.com/ ) from ... the company said it decided to do so ... devices remain uncertain.* , “In light of mounting ...
(Date:7/31/2014)... July 31, 2014 Infection prevention and ... and maintenance of products in the pharma, medical device, ... by using various products and equipment types; the two ... various materials and products. , The world market ... forecast to post a CAGR of about 7.5% through ...
(Date:7/31/2014)... HealthDay Reporter THURSDAY, July 31, 2014 (HealthDay ... has shown an increased risk of spreading undetected cancers in ... market. In a letter that was to be sent ... that its laparoscopic power morcellators be returned to the company, ... of new morcellators had been suspended in April after the ...
Breaking Medicine News(10 mins):Health News:Fitness on the Go's Rewards Program Helps Clients Reach Their Goals 2Health News:New Snoring Mouthpiece Reviews from VitalSleep 2Health News:Uterine Morcellation Controversy Grows, as Bernstein Liebhard LLP Notes Johnson & Johnson Decision to Withdraw Power Morcellators from Market 2Health News:Uterine Morcellation Controversy Grows, as Bernstein Liebhard LLP Notes Johnson & Johnson Decision to Withdraw Power Morcellators from Market 3Health News:Infection Prevention and Control Market to Post about 7.5% CAGR through 2018, States Infiniti Research in Its Study Published at MarketPublishers.com 2Health News:Infection Prevention and Control Market to Post about 7.5% CAGR through 2018, States Infiniti Research in Its Study Published at MarketPublishers.com 3Health News:J&J Pulls Hysterectomy Tool Tied to Cancer Risk From Market 2Health News:J&J Pulls Hysterectomy Tool Tied to Cancer Risk From Market 3
... associated with enhanced communications between families and caregivers, ... for children dying from cancer, according to study ... Hospital Boston. , Published in the April 1 ... study,s findings also suggest that the parents were ...
... that Planned Parenthood affiliates in Florida,have been falsifying ... show,that what happened in California is not an ... Life League,renewed its call for a national investigation ... Florida allege falsified annual,reports., "It,s outrageous that ...
... Consultancy to Address Circle of Patient Care, ... Mike Marolt, president of St.,Paul-based eq-life(R), announced ... to provide pharmacy operations consulting to,hospital organizations ... a,multi-year agreement with Omaha-based Alegent Health to ...
... and TAMPA, Fla., March 28 ... LLC (myMatrixx) are pleased to,announce an ... bill review program and myMatrixx,s pharmacy ... first fully-integrated and automated,program between a ...
... Darwin,Professional Underwriters, Inc. (Darwin) (NYSE: DR ... Romano, who served as its senior vice ... Romano has become,associated with a competing professional ... http://www.newscom.com/cgi-bin/prnh/20060829/NETU014LOGO ), The company ...
... March 28 Conseco, Inc. (NYSE:,CNO) announced today that ... for,the year ended December 31, 2007 with the Securities ... common stock for 2007 was $194.0,million, compared to the ... 2008 preliminary results. The reported net loss applicable to,common ...
Cached Medicine News:Health News:Study finds improvement in the care of children with cancer at the end of life 2Health News:Study finds improvement in the care of children with cancer at the end of life 3Health News:American Life League: Planned Parenthood Scandals 'Widespread' 2Health News:eq-life(R) and Fairview Pharmacy Services Announce Multi-Year Consulting Contract with Alegent Health 2Health News:eq-life(R) and Fairview Pharmacy Services Announce Multi-Year Consulting Contract with Alegent Health 3Health News:Rising Medical Solutions Partners With myMatrixx to Deliver Integrated Pharmacy Management Solutions 2Health News:Darwin Announces Departure of Senior Vice President 2Health News:Conseco Files 10-K and Sets Earnings Release Date 2
(Date:7/31/2014)... NEW YORK und KISSING, Deutschland, ... ein Hersteller und Distributor eines computerunterstützten („robotischen") ... Nachum (Homi) Shamir , ein weltweit ... seines Leitungs- und Kontrollgremiums zum Unternehmen stößt. ... Shamir ist ein hochangesehener ...
(Date:7/31/2014)... July 31, 2014 Orexigen® Therapeutics, Inc. (Nasdaq: ... the second quarter 2014, on Thursday, August 7, 2014 ... a live webcast and conference call at 8:00 a.m. ... management will host the call and webcast to discuss ... may be accessed by calling (800) 708-4540 (domestic) or ...
(Date:7/31/2014)... 2014 Nutrastar International Inc. (OTCQB: NUIN; "Nutrastar" ... premium branded consumer products, including commercially cultivated Cordyceps Militaris ... announced the signing of its first distributor for its ... Hubei Province located ... . The contract with the ...
Breaking Medicine Technology:invendo medical holt Nachum (Homi) Shamir in den Board of Directors des Unternehmens 2invendo medical holt Nachum (Homi) Shamir in den Board of Directors des Unternehmens 3Orexigen Therapeutics to Host Second Quarter 2014 Financial Results Conference Call and Webcast 2Nutrastar Signs First Distributor for New Cordyceps Powder Solution Product, Expands Reach to Central China 2Nutrastar Signs First Distributor for New Cordyceps Powder Solution Product, Expands Reach to Central China 3Nutrastar Signs First Distributor for New Cordyceps Powder Solution Product, Expands Reach to Central China 4
... and PARIS, Feb. 24, 2011 /PRNewswire-Asia-FirstCall/ -- Sanofi-aventis (EURONEXT: ... it has completed the previously announced acquisition of BMP ... stockholders held today, BMP Sunstone stockholders approved the adoption ... Star 2010, Inc., a wholly owned subsidiary of sanofi-aventis, ...
... Conn., Feb. 24, 2011 Mira Dx announced today that ... acceptance of a pivotal breast cancer study in the January ... BRCA1 coding sequence mutations are associated with breast ... less than 5% of breast cancer risk. The research identified ...
Cached Medicine Technology:Sanofi-Aventis Announces Approval and Closing of BMP Sunstone Acquisition Creating a Strong Consumer Health Care Platform in China 2Mira Dx Licenses Triple Negative Breast Cancer Risk Variant from Yale University 2
HbA1c / HbCalibrator...
Control Plasma for Assays of Low MolecularWeight Heparins (LMWH) using Anti-Xa Method on STA© Analyzers....
... Abnormal Control Plasmas for ... D-dimer and Free Protein ... For use with STA© ... D-DI (#0515) andSTA© LIATEST© ...
CRP Full Range (0.1-160mg/l)...
Medicine Products: